Baker Botts’ Antitrust Team Guides Merck Animal Health in Acquisition of Virbac’s U.S. Rights to SENTINEL Brand of Combination Parasiticides
WASHINGTON, D.C., May 13, 2020 - Baker Botts L.L.P., a leading international law firm, announced today that its client, Merck Animal Health, a division of Merck & Co., Inc. (NYSE:MRK), has signed a definitive agreement with Virbac (NYSE Euronext:VIRP) under which Merck Animal Health would acquire for $400 million the U.S. rights to SENTINEL FLAVOR TABS and SENTINEL SPECTRUM Chews in the Companion Animal category. The transaction is expected to close by mid-year 2020, subject to antitrust clearance and other customary closing conditions. Merck Animal Health’s press release can be found here.
The Baker Botts antitrust team was led by Antitrust Group Co-Chair Stephen Weissman, partner Michael Perry, and associate Timothy Singer.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm whose lawyers practice throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.